<DOC>
	<DOCNO>NCT03053297</DOCNO>
	<brief_summary>This observational cohort study patient locally advance metastatic NSCLC ( non-small cell lung cancer ) . Patients recruit participate site Europe , Asia , Canada . The study include 2 patient cohort .</brief_summary>
	<brief_title>Observational Study Patients With Locally Advanced Metastatic NSCLC ( Non-Small Cell Lung Cancer )</brief_title>
	<detailed_description>Study Design This observational cohort study patient locally advance metastatic NSCLC ( non-small cell lung cancer ) . Patients recruit participate site Europe , Asia , Canada . Patients meet study inclusion/exclusion criterion select 24-month enrolment period per country follow enrolment study death , loss follow-up , withdrawal consent study end date ( whichever occurs early ) . Data Sources Data collect follow enrolment study enter electronic case report form ( eCRF ) . All data collect use patient medical record . The investigator responsible ensuring require data collect enter eCRF . The site collect patient questionnaire data upload accord data entry procedure . Study Population - Adult male female patient ( accord age majority/adulthood define local regulation ) give write informed consent per local regulation . - The primary cohort include patient EGFR ( epidermal growth factor receptor ) mutation-positive locally advanced metastatic NSCLC progress receive front-line EGFR-TKI ( tyrosine kinase inhibitor ) therapy ( e.g. , gefitinib , erlotinib , afatinib , icotinib ) . - Additionally , secondary cohort patient include patient newly diagnose locally advanced metastatic NSCLC treatment naive patient diagnose early stage progress metastatic NSCLC selection period . Exposures There specific drug exposure intervention evaluate , cohort eligibility ( cohort ) exposure-based , rather disease-based . All molecular testing treatment discretion treat physician . Study Measures Outcomes - Patient demographic clinical characteristic - Molecular testing pattern outcomes - Treatment pattern - Physician-reported clinical outcome - Cancer-related health care utilization - Treatment- biopsy-related complication - CNS metastasis ( brain metastasis leptomeningeal metastasis ) treatment associate CNS ( central nervous system ) metastases - HRQoL ( Health Related Quality Life ) symptoms Precision Sample Size Estimations For primary cohort minimum sample size recommend conduct country-level analysis 200 patient per country . This base precision estimation calculation categorical study measure ( % patient test ) allow maximum - 8.3 % precision ( i.e. , assume 50 % undergoing molecular test ) around point estimate categorical measure . For secondary cohort minimum sample size recommend conduct country-level analysis 300 patient determine use precision estimate calculate categorical ( % patient test ) time-to-event ( overall survival ) measure . The overall study include approximately 2800-3300 patient across participate country across primary ( 1200-1300 patient ) secondary ( 1600-2000 patient ) cohort . Statistical Analysis No formal hypothesis test specify . Study measure include patient demographic clinical characteristic , molecular testing pattern , treatment sequence pattern , physician-reported outcome ( overall survival ) patient-reported outcome ( HRQoL ) report primary secondary cohort , unless indicate otherwise . Continuous study measure ( e.g. , age , duration therapy ) report descriptively mean , standard deviation , median , minimum maximum . Frequencies percentage use document categorical measure interest ( e.g. , number proportion patient post progression molecular test , number proportion patient T790M mutation ) include 95 % CIs key outcome variable . Kaplan-Meier curve median survival estimate , overall exploratory basis clinical treatment characteristic interest ( provide sufficient event available ; e.g. , chemotherapy vs. target therapy ) pre-specified statistical analysis plan .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Provision write informed consent patient consent within 6 week index date . Adult male female subject ( accord age majority/adulthood define local regulation ) Enrolment study prohibit participation non interventional study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>EGFR</keyword>
	<keyword>EGFR mutation</keyword>
	<keyword>EGFRm</keyword>
	<keyword>EGFR-TKI</keyword>
	<keyword>Health care resource utilization</keyword>
	<keyword>Health-Related Quality Life</keyword>
	<keyword>Locally advanced metastatic lung cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Non-Small Cell Lung Cancer</keyword>
	<keyword>Observational study</keyword>
	<keyword>Osimertinib</keyword>
	<keyword>Personalized medicine</keyword>
	<keyword>PRO</keyword>
	<keyword>Patient Reported Outcome</keyword>
	<keyword>Resistance</keyword>
	<keyword>T790M</keyword>
	<keyword>Carcinoma , Non-Small-Cell Lung</keyword>
	<keyword>Carcinoma , Bronchogenic</keyword>
	<keyword>Bronchial Neoplasms</keyword>
	<keyword>Lung Neoplasms</keyword>
	<keyword>Respiratory Tract Neoplasms</keyword>
	<keyword>Thoracic neoplasm , Neoplasms site</keyword>
	<keyword>Lung disease</keyword>
	<keyword>Respiratory Tract disease</keyword>
	<keyword>Cancer Chemotherapy</keyword>
	<keyword>Combination Chemotherapy</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Radiation</keyword>
</DOC>